Increased NOTCH3 protein acetylation levels by suberoylanilide hydroxamic acid (SAHA), a histone deacetylase (HDAC) inhibitor, decreases NOTCH3 protein expression resulting in reduced tumour growth and enhanced sensitisation of urothelial cancer cells to cisplatinum. Here, NOTCH3 is linked to neoplasm.